Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit?

International Immunopharmacology

Volumn 36, Issue , 2016, Pages 291-299

  Brown, K Alun ^a,b,d   Brown, Geraint A ^c   Lewis, Sion M ^a,b   Beale, Richard ^a,b   Treacher, David F ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Immunopathology; Sepsis; Therapy

Indexed keywords

ALPHA INTERFERON; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HUMAN; META ANALYSIS (TOPIC); MULTIPLE ORGAN FAILURE; NONHUMAN; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; REVIEW; SEPSIS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PARACRINE SIGNALING; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PARACRINE COMMUNICATION; SEPSIS;

EID: 84969530894     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.04.041     Document Type: Review

References (153)

1. D.C. Angus, and T. Van Der Poll Severe sepsis and septic shock N. Engl. J. Med. 369 2013 840 851
2. Surviving sepsis campaign guidelines to management of severe sepsis and septic shock Intensive Care Med. 30 2004 536 555
3. A. Kotdsaki, and E.J. Giamarellos-Bourboulis Emerging drugs for the treatment of sepsis Expert Opin. Emerg. Drugs 17 2012 379 391
4. W.J. Wiersinga Current insights in sepsis: from pathogenesis to new treatment targets Curr. Opin. Crit. Care 17 2011 480
5. J. Leentjens, M. Kox, J. Van Der Hoeven, G. Netea, and M.G.P. Pickkers Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am. J. Respir. Crit. Care Med. 187 2013 1287 1293
6. D.J. Stearns-Kurosacwa, M.F. Osuchowski, C. Valentine, S. Kurosawa, and D.G. Remick The pathogenesis of sepsis Annu. Rev. Pathol. 6 2011 19 48
7. F. Fourrier Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit. Care Med. 40 2012 2704 2708
8. G.R. Bernard, J.L. Vincent, P.F. Latrerre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-Rodriguez, J.S. Steingrub, G.E. Garber, J.D. Helterbrand, E.W. Ely, and C.J. Fisher Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis N. Engl. J. Med. 344 2001 699 709
9. D.C. Angus The search for effective therapy for sepsis: back to the drawing board? JAMA 306 2011 2614 2615
10. N. Aikawa Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults Nippon Geka Gakkai Zasshi 40 1996 702 709
11. F. Fourier Severe sepsis, coagulation and fibrinolysis: dead end or one way? Crit. Care Med. 40 2012 2704 2708
12. E. Rivers, S. Nguyen, S. Havstad, J. Ressler, A. Muzzin, B. Knoblich, E. Peterson, and M. Tomlanovich Early goal directed therapy in the treatment of severe sepsis and septic shock N. Engl. J. Med. 345 2001 1368 1377
13. J. Carre, M. Singer, and S. Moncada Nitric oxide E. Abraham, M. Singer, Mechanisms of sepsis-induced organ dysfunction and recovery 2007 Springer Berlin, Heidelberg 76 95
14. D. Dimasi, W.Y. Sun, and B. C.S Neutrophil interactions with the vascular endothelium Int. Immunopharmacol. 17 2013 1167 1175
15. A.E. Williams, and R.C. Chambers The mercurial nature of neutrophils: still an enigma in ARDS? Am. J. Phys. Lung Cell. Mol. Phys. 306 2014 217 230
16. K.A. Brown, S.D. Brain, J.D. Pearson, J.D. Edgeworth, S.M. Lewis, and D.F. Treacher Neutrophils in development of multiple organ failure in sepsis Lancet 368 2006 157 169
17. S. Lewis, D.F. Treacher, L. Bergmeier, S.D. Brain, J.D. Pearson, and K.A. Brown Plasma from patients with sepsis upregulate the expression of CD49d and CD64, impairs shedding of CD62L and to enhance binding Am. J. Respir. Cell Mol. Biol. 40 2007 724 732
18. S. Harbeth, K. Holeckova, C. Froidevaux, D. Pittet, B. Ricou, G.E. Grau, L. Vadas, and J. Pugin Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients admitted with suspected sepsis Am. J. Respir. Crit. Care Med. 164 2001 396 402
19. J.A. Hazelzet, R.F. Kornelisse, T.C. van der Pouw Kraan, K.F. Joosten, E. van der Voort, G. van Mierlo, M.H. Suur, W.C. Hop, R. de Groot, and C.E. Hack Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease Cytokine 9 1997 711 716
20. M. Bosmann, and P.A. Ward Therapeutic potential of targeting IL-17 and IL-23 in sepsis Clinical Translational Medicine 1 2012 1 4
21. S.K. Tschoeke, A. Oberhoizer, and L.L. Moldawer Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis Crit. Care Med. 34 2006 1225 1233
22. T.M. Bingold, E. Ziesche, B. Scheller, C.D. Sadik, K. Franck, L. Just, S. Sartorius, M. Wahrmann, H. Wissing, B. Zwissler, J. Pfeilschifter, and H. Mühl Interleukin - 22 detected in patients with abdominal sepsis Shock 34 2010 337 340
23. P. Damas, A. Reuter, P. Gysen, J. Demonty, M. Lamy, and P. Franchimont Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans Crit. Care Med. 17 1989 975 978
24. S. Karlsson, V. Pettila, J. Tenhunen, R. Laru-Sompa, M. Hynninen, and E. Ruokenen HMGB1 as a predictor of organ dysfunction in patients with severe sepsis Intensive Care Med. 34 2008 1046 1053
25. C.C. Chuang, S.T. Wang, W.C. Chen, L.I. Hor, and A.Y. Chuang Increases in serum macrophage migration inhibitory factor in patients with severe sepsis predict early mortality Shock 27 2007 503 506
26. G. Matera, R. Puccio, A. Giancotti, A. Quirino, M.C. Pulicari, E. Zicca, S. Caroleo, A. Renzulli, M.C. Liberto, and A. Focà Impact of interleukin-10, soluble CD25 and interferon-γ on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study Crit. Care 17 2 2013 Apr 5 R64 10.1186/cc12596
27. W.H. Tsai, C.H. Shih, Y.B. Yu, and H.C. Hsu Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin J.Chin.Med.Assoc 76 9 2013 486 490 10.1016/j.jcma.2013.05.004 (Epub 2013 Jun 14)
28. L.M. Samson, U.D. Allen, W.D. Creery, and F. Diaz-Mitoma Singh RN elevated interleukin-1 receptor antagonist levels in pediatric sepsis syndrome J. Pediatr. 131 1997 587 591
29. J.T. DiPiro, T.R. Howdieshell, J.K. Goddard, D.B. Callaway, and R.G. Hamilton Mansberger AR Jr association of interleukin-4 plasma levels with traumatic injury and clinical course Arch. Surg. 130 1995 1159 1162
30. G. Monneret, M.E. Finck, F. Vennet, A.L. Debard, J. Bohé, and J. Bienvenu Lepape a the anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high IL-10 concentration Immunol. Lett. 95 2004 193 198
31. N. Collighan, P.V. Giannoudis, O. Kourgeraki, S.L. Perry, P.J. Guillou, and M.C. Bellamy Interleukin 13 and inflammatory markers in human sepsis Br. J. Surg. 19 2004 762 768
32. C. Marie, M. Cavaillon, and M.R. Losser Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome Ann. Intern. Med. 125 1996 520 521
33. V. Petilla, M. Hynninen, O. Takkunen, P. Kuusela, and M. Valtonen Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis Intensive Care Med. 28 2002 1220 1225
34. K. Doi, A. Leelahavanichukul, P.S.T. Yuen, and R.A. Star Animal models of sepsis and sepsis-induced kidney injury J. Clin. Invest. 10 2009 2868 2878
35. C.A. Gogos, E. Drosou, H.P. Bassaris, and A. Skoutelis Pro versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options J. Infect. Dis. 181 2000 176 180
36. R.S. Hotchkiss, and M.D. Opal Immunotherapy for sepsis - a new approach against and ancient foe N. Engl. J. Med. 363 2010 87 89
37. A.M. Bernard, and G.R. Bernard The immune response: targets for the treatment of severe sepsis Int. J. Inflamm. 2012 2012 697592
38. M.J. Delano, T. Thayer, S. Gabrilovich, K.M. Kelly-Scumpia, R.D. Winfield, P.O. Scumpia, A.G. Cuenca, E. Warner, S.M. Wallet, M.A. Wallet, K.A. O'Malley, R. Ramphal, M. Clare-Salzer, P.A. Effron, C.E. Mathews, and L.L. Moldawer Sepsis induces early alterations in innate immunity that impact mortality to secondary infection J. Immunol. 186 2011 195 202
39. J.S. Boomer, J. Shuherk-Shaffer, R.S. Hotchkiss, and J.M. Green A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis Crit. Care 16 2012 112
40. R.G. Westendorp, J.A. Langermans, T.W. Huizinga, A.H. Elouali, C.L. Verweij, D.I. Boomsma, and J.P. Vandenbroucke Genetic influence on cytokine production and fatal meningococcal disease Lancet 349 1997 170 173
41. J.M. Cavaillon Pathophysiological role of pro- and anti-inflammatory cytokines in sepsis Sepsis 2 1998 127 140
42. T. Van der Poll, H.R. Buller, H. Cate, C.H. Wortel, K.A. Bauer, S.J. van Deventer, C.E. Hack, H.P. Sauerwein, R.D. Rosenberg, and J.W. Cate Activation of coagulation after administration of tumour necrosis factor to normal subjects N. Engl. J. Med. 322 1990 1622 1627
43. R.N. Maini, and P.C. Taylor Anti-cytokine therapy for rheumatoid arthritis Annu. Rev. Med. 51 2000 207 229
44. W.J. Sandborn, S.B. Hanauer, P. Rutgeerts, R.N. Fedorak, M. Lukas, D.G. MacIntosh, R. Panaccione, D. Wolf, J.D. Kent, B. Bittle, J. Li, and P.F. Pollack Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
45. C.J. Fisher, S.M. Opal, J.F. Dhainaut, S. Stephens, J.L. Zimmerman, P. Nightingale, S.J. Harris, R.M. Schein, E.A. Panacek, and J.L. Vincent Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine level in patients with sepsis. The CB0006 sepsis syndrome study group Crit. Care Med. 21 1993 318 327
46. E. Abraham, R. Wunderink, and H. Silverman Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicentre clinical trial JAMA 273 1995 934 941
47. J.F. Dhainaut, J.L. Vincent, C. Richard, P. Lejeune, C. Martin, L. Fierobe, S. Stephens, U.M. Ney, and M. Sopwith CDP57 a humanized antibody to human tumour necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock Crit. Care Med. 23 1995 1461 1469
48. J. Cohen, and J. Carlet INTERSEPT: an international, multicentre, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis Crit. Care Med. 24 1996 1431 1440
49. C.J. Fisher Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, J.C. Sadoff, E. Abraham, R.M. Schein, and E. Benjamin Treatment of septic shock with the tumour necrosis factor:fc fusion protein N. Engl. J. Med. 334 1996 1697 1702
50. K. Reinhart, C. Wiegand-Löhnert, F. Grimminger, M. Kaul, S. Withington, D. Treacher, J. Eckart, S. Willatts, C. Bouza, D. Krausch, F. Stockenhuber, J. Eiselstein, L. Daum, and J. Kempeni Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 1995F, in patients with sepsis and septic shock: a multi-centre, randomized, placebo-controlled, dose-ranging study Crit. Care Med. 24 1996 733 742
51. E. Abraham, M.P. Glauser, T. Butler, J. Garbino, D. Gelmont, P.F. Laterre, K. Kudsk, H.A. Bruining, C. Otto, E. Tobin, C. Zwingelstein, W. Lesslauer, and A. Leighton P55 tumour necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock JAMA 277 1997 1531 1538
52. E. Abraham, A. Anzueto, G. Gutierrez, S. Tessler, G. San Pedro, R. Wunderink, A. Dal Nogare, S. Nasraway, S. Berman, R. Cooney, H. Levy, R. Baughman, M. Rumbak, R.B. Light, L. Poole, R. Allred, J. Constant, J. Pennington, and S. Porter Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock Lancet 351 1998 929 933
53. M.A. Clark, L.D. Plank, A.B. Connolly, S.J. Streat, A.A. Hill, R. Gupta, D.N. Monk, A. Shenkin, and G.L. Hill Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis a randomised clinical trial Crit. Care Med. 26 1998 1650 1659
54. J. Gallagher, C. Fisher, B. Sherman M. Munger, B. Meyers, T. Ellison, S. Fischkoff, W.T. Barchuk, L. Teoh, and R. Velagapudi A multi-centre, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome Intensive Care Med. 27 2001 1169 1178
55. K. Reinhart, T. Menges, and B. Gardlund Randomized, placebo-controlled trail of the anti-tumor necrosis factor antibody fragment afelimomab in hyper-inflammatory response during severe sepsis: the RAMSES study Crit. Care Med. 29 2001 765 769
56. V.L. Butty Roux-Lombard P, Garbino J, Dayer J-M, Ricou B and the Geneva sepsis network. Anti-inflammatory response after infusion of p55 soluble tumour necrosis factor fusion protein for severe sepsis Eur. Cytokine Netw. 14 2003 15 19
57. E.A. Panacek, J.C. Marshall, T.E. Albertson, D.H. Johnson, R.D. MacArthur, M. Miller, W.T. Barchuk, S. Fischkoff, M. Kaul, L. Teoh, L. Van Meter, L. Daum, S. Lemeshow, G. Hicklin, and C. Doig Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels Crit. Care Med. 32 2004 2173 2182
58. T.W. Rice, A.P. Wheeler, P.E. Morris, H.L. Paz, J.A. Russell, T.R. Edens, and G.R. Bernard Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis Crit. Care Med. 34 2006 2271 2281
59. P.E. Morris, B. Zeno, A.C. Bernard, X. Huang, S. Das, T. Edeki, S.G. Simonson, and G.R. Bernard A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock Crit. Care 16 2012 R31
60. N. Aikawa, T. Takahashi, S. Fujimi, T. Yokoyama, K. Yoshihara, T. Ikeda, D. Sadamitsu, M. Momozawa, and T. Maruyama A phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock J. Infect. Chemother. 19 2013 931 940
61. C.J. Fisher, J.F. Dhainaut, S.M. Opal, J.P. Pribble, R.A. Balk, G.J. Slotman, T.J. Iberti, E.C. Rackow, M.J. Shapiro, R.L. Greenman, E.C. Rackow, M.J. Shapiro, and R.L. Greenman Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1RA Sepsis Syndrome Study Group JAMA 271 1994 1836 1843
62. C.J. Fisher, G.J. Slotman, S.M. Opal, J.P. Pribble, R.C. Bone, G. Emmanuel, D. Ng, D.C. Bloedow, and M.A. Catalano Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial Crit. Care Med. 22 1 1994 12 21
63. S.M. Opal, C.J. Fisher Jr., J.F. Dhainaut, J.L. Vincent, R. Brase, S.F. Lowry, J.C. Sadoff, G.J. Slotman, H. Levy, R.A. Balk, M.P. Shelly, J.P. Pribble, J.F. LaBrecque, J. Lookabaugh, H. Donovan, H. Dubin, R. Baughman, J. Norman, E. DeMaria, K. Matzel, E. Abraham, and M. Seneff Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicentre trial Crit. Care Med. 25 1997 1115 1124
64. S. Lv, M. Han, R. Yi, S. Kwon, C. Dai, and R. Wang Anti-TNFα therapy for patients with sepsis: a systematic meta-analysis Int. J. Clin. Pract. 2014 10.1111/ijcp.12382
65. E. Abraham Why immunomodulatory therapies have not worked in sepsis Intensive Care Med. 25 1999 556 566
66. K. Reinhart, and K. Waheedullah Anti-tumour necrosis factor therapy in sepsis: update on clinical trials and lessons learned Crit. Care Med. 29 Supplement 1 2001 S121 S125
67. T. Gustot Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response Curr. Opin. Crit. Care 17 2011 153 159
68. J. Cohen, and E. Abraham Microbiologic findings and correlations with serum tumour necrosis factor-α in patients with severe sepsis and septic shock J.I.D 180 1999 116 121
69. P.Q. Eichacker, C. Parent, A. Kalil, C. Esposito, X. Cui, S.M. Banks, E.P. Gerstenberger, Y. Fitz, R.L. Danner, and C. Natanson Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis Am. J. Respir. Crit. Care Med. 166 2002 1197 1205
70. B. Beurler, I.W. Milsark, and A.C. Cerami Passive immunization against cachectin/tumour necrosis factor protects mice from lethal effect of endotoxin Science 229 1985 869 871
71. R. Marquez-Valasco, R. Bojalil, A. Buelna, F. Flores-Guzman, J. Estevez-Ramirez, J. Laguna, A.M. Hernandez, A. Diaz-Quninonez, and J.F. Paniagua-Solis Anti-tumour necrosis factor alpha F(ab′)2 antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome Inflamm. Res. 55 2006 378 384
72. K. Ohlsson, P. Bjork, M. Bergenfeldt, R. Hageman, and R.C. Thompson Interleukin-1 receptor antagonist reduces mortality from endotoxin shock Nature 348 1990 550 552
73. G. Wakabayashi, J.A. Gelfand, J.F. Burke, R.C. Thompson, and C.A. Dinarello A specific receptor antagonist for interleukin - 1 prevents Escerichia coli-induced shock FASEB J. 5 1991 338 343
74. K.J. Tracey, Y. Fong, D.G. Hesse, K.R. Manogue, A.T. Lee, G.C. Kuo, S.F. Lowry, and A. Cerami Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia Nature 330 1987 662 664
75. Y. Fong, K.J. Tracey, L.L. Moldawer, D.G. Hesse, K.B. Manogue, J.S. Kenney, A.T. Lee, G.C. Kuo, A.C. Allison, and S.F. Lowry Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia J. Exp. Med. 170 1989 1627 1633
76. E. Fischer, M.A. Marano, K.J. Van Zee, C.S. Rock, A.S. Hawes, W.A. Thompson, L. DeForge, J.S. Kenney, D.G. Remick, and D.C. Bloedow Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia J. Clin. Invest. 89 1992 1551 1557
77. L.B. Hinshaw, P. Tekamp-Olson, A.C. Chang, P.A. Lee, F.B. Taylor, C.K. Murray, G.T. Peer, T.E. Emerson, R.B. Passey, G.C. Kuo, F.B. Taylor Jr., and T.E. Emerson Jr. Survival of primates in LD100 septic shock following therapy with antibody to tumour necrosis factor (TNF alpha) Circ. Shock. 30 1990 279 292
78. L.B. Hinshaw, T.E. Emerson Jr., F.B. Taylor, P. Tekamp-Olson, A.C. Chang, M. Duerr, G.T. Peer, D.J. Flournoy, G.L. White, S.D. Kosanke, and C.K. Murray Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody J. Trauma. 33 1992 568 573
79. K.J. Van Zee, L.L. Moldawer, H.S. Oldenburg, W.A. Thompson, S.A. Stackpole, W.J. Montegut, M.A. Rogy, C. Meschter, H. Gallati, C.D. Schiller, W.F. Richter, H. Loetscher, A. Ashkenazi, S.M. Chamow, F. Wurm, S.E. Calvano, S.F. Lowry, and W. Lesslauer Protection against lethal Escherichia coli bacteremia in baboons (Papio Anubis) by pretreatment with a 55-kDa TNF receptor (CD120a) Ig fusion protein, Ro 45-2081 J. Immunol. 156 1996 2221 2230
80. C.C. Solorzano, A. Kaibara, P.J. Hess, P.D. Edwards, R. Ksontini, A. Abouhamze, S. McDaniel, J. Frazier, D. Trujillo, G. Kieft, J. Seely, T. Kohno, M.E. Cosenza, M. Clare-Salzler, S.L. MacKay, S.W. Martin, L.L. Moldawer, and C.K. Edwards 3rd. Pharmokinetics, immunogenicity and efficacy of dimeric TNFR binding proteins in healthy and bacteremic baboons J. Appl. Physiol. 84 1998 1119 1130
81. J.J. Rosenberg, S.W. Martin, J.E. Seely, O. Kinstler, G.C. Gaines, K. Fukuzuka, J. Rose, T. Kohno, W.J. Boyle, A. Nelson, G.L. Kieft, W.S. Marshall, U. Feige, J. Gasser, J. St Clair, J. Frazier, A. Abouhamze, L.L. Moldawer, and C.K. Edwards 3rd. Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-1) construct in the baboon J. Appl. Physiol. 91 2001 2213 2223
82. M.K. Eskandari, G. Bolgos, C. Miller, D.T. Nguyen, L.E. DeForge, and D.G. Remick Anti-tumour necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia J. Immunol. 148 1992 2724 2730
83. J.S. Boomer, J.M. Green, and R.S. Hotchkiss The changing immune system in sepsis. Is individualized immune-modulatory therapy the answer? Virulence 5 2014 45 56
84. M. Bosmann, and A. Ward The inflammatory response in sepsis Trends Immunol. 34 2013 129 136
85. E. Rimmer, B. Houston, A. Kumar, A. Abou-Setta, C. Friesen, J. Marshall, G. Rock, A. Turgeon, D. Cook, D. Houston, and R. Zarychanski The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and meta-analysis Crit. Care 18 2014 1 8
86. H. Shiga, H. Hirasawa, O. Nishida, S. Oda, M. Nakamura, K. Mashiko, K. Matsuda, N. Kitamura, Y. Kikuchi, and N. Fuke Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report Blood Purif. 38 2015 211 218
87. X.M. Fang, S. Schroder, A. Hoeft, and F. Stuber Comparisons of two polymorphisms of the interleukin-1 gene family; interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis Crit. Care Med. 27 1999 1330 1334
88. K. Baghel, R. Srivastava, A. Chandra, S. Goel, J. Agrawal, H. Kazmi, and S. Raj TNF-α, IL-6, and IL-8 cytokines and their association with TNF-α-308 G/a polymorphism and postoperative sepsis J. Gastrointest. Surg. 18 2014 1486 1494
89. T. Calandra, B. Echenacher, D. Le Roy, J. Pugin, C.N. Metz, L. Hultner, D. Heumann, D. Männel, R. Bucala, and M.P. Glauser Protection from septic shock by neutralisation of macrophage inhibitory factor Nat. Med. 6 2000 164 170
90. H. Yang, M. Ochani, J.H. Li, X.L. Qiang, M. Tanovic, H.E. Harris, S.M. Susarla, L. Ulloa, H. Wang, C.R. Diraimo, C.J. Czura, H.C. Wang, J. Roth, W. HS, F. M.P, F. M.J, U. Andersson, and K.J. Tracey Reversing established sepsis with antagonists of endogenous high-mobility group box 1 Proc. Natl. Acad. Sci. U. S. A. 101 2004 296 301
91. I. Cvetovic, and S. Stosic-Grujicic Neutralisation of macrophage inhibitory factor - novel approach for the treatment of inflammatory disorders Int. Immunopharmacol. 6 2006 1527 1534
92. T. Roger, J. Delaloye, A.L. Chanson, M. Giddey, D. Le Roy, and T. Calandra Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis J. Infect Dis. 15 2013 331 339
93. S. Tohyama, S. Onodera, H. Tohyama, K. Yasuda, J. Nishihira, Y. Mizue, A. Hamasaka, R. Abe, and Y. Koyama A novel DNA vaccine-targeting macrophage migration inhibitory factor improves the survival of mice with sepsis Gene Ther. 15 2008 1512 1513
94. Y. Al-Abed, D. Dabideen, B. Aljabari, A. Valster, D. Messemer, M. Ochani, M. Tanovic, K. Ochani, M. Bacher, F. Nicoletti, C. Metz, V.A. Pavlov, E.J. Miller, and K.J. Tracey ISO - 1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis J. Biol. Chem. 280 2005 36541 36544
95. L. Xu, Y. Li, H. Sun, X. Zhen, C. Qiao, S. Tian, and T. Hou Current developments of macrophage migration inhibitory factor (MIF) inhibitors Drug Discov. Today 18 2013 592 600
96. M. Lotze, and K.J. Tracey High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal Nat. Rev. Immunol. 5 2005 331 342
97. J.S. Bae Role of high mobility group box 1 in inflammatory disease: focus on sepsis Arch. Pharm. Res. 35 2012 1511 1523
98. L.F. Gentile, and L.L. Moldawer HMGB1 as a therapeutic target for sepsis: it's all in the timing Expert Opin. Ther. Targets 18 2014 243 245
99. M. Yang, L. Cao, M. Xie, Y. Yu, R. Kang, L. Yang, M. Zhao, and D. Tang Chloroquine inhibits HMGB1 inflammatory signalling and protects mice from lethal sepsis Biochem. Pharmacol. 86 3 2013 Aug 1 410 418 10.1016/j.bcp.2013.05.013 (Epub 2013 May 22)
100. S. Kato, M.H. Hussein, H. Kakita, T. Goto, G.A. Daoud, T. Kato, T. Sugiara, M. Nobata, Y. Nakajima, T. Endo, K. Mizuno, T. Ito, I. Kato, S. Suzuki, and H. Togari Edaravone, a novel free radical scavenger, reduces high-mobility group box 1 and prolongs survival in a neonatal sepsis model Shock 32 2009 586 592
101. T.H. Kim, S. Ku, and J. Bae Persicarin is anti-inflammatory mediator against HMGB1-induced inflammatory responses in HUVECs and in CLP-induced sepsis mice J. Cell. Physiol. 228 2013 696 703
102. C. Lee, S. Yoon, and S. Lee Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis Mol. Med. 18 2013 1437 1448
103. S. Mera, D. Tatulescu, C. Cismaru, C. Bondor, A. Slavcovici, V. Zanc, D. Carstina, and M. Oltean Multiplex cytokine profiling in patients with sepsis APMIS 119 2011 155 163
104. R. Fudala, A. Krupa, D. Stankowska, T.C. Allen, and A.K. Kurdowska Anti-interleukin-8 autoantibody: interleukin-8 immune complexes in acute lung injury/acute respiratory distress syndrome Clin. Sci. 114 2008 403 412
105. D.J. Cua, and C.M. Tato Innate IL-17 producing cells: the sentinels of the immune system Nat. Rev. Immunol. 10 2010 479 489
106. D.R. Chung, D.L. Kasper, R.J. Panzo, T. Chitnis, M.J. Grusby, M.H. Sayegh, and A.O. Tzianabos CD4 + Tcells mediate abscess formation in intra-abdominal sepsis by and IL-17-dependent mechanism J. Immunol. 170 2003 1958 1963
107. K. Shibata, H. Yamada, H. Hara, K. Kishihara, and Y. Yoshikai Resident Vdelta 1 + gammadelta T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production J. Immunol. 178 2007 4466 4472
108. M. Tidswell, and S. Larosa P. 2011. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis Expert Rev. Anti-Infect. Ther. 9 2011 507 520
109. S.M. Opal, P. Laterre, B. Francois, S.P. Larosa, D.C. Angus, J. Mira, X. Wittebole, T. Dugernier, D. Perrotin, and M. Tidswell Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial J. Am. Med. Assoc. 309 2013 1154 1162
110. H. Yang, W. Zhang, H. Pan, H.G. Feldser, E. Lainez, C. Miller, S. Leung, Z. Zhong, H. Zhao, S. Sweitzer, T. Considine, T. Riera, V. Suri, B. White, E. JL, V. GP, and C. Loh SIRT 1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-$\kappa$B activity PLoS One 7 9 2012 e46364 10.1371/journal.pone.0046364 (Epub 2012 Sep 28)
111. S.P. Larosa, and S.M. Opal Immune aspects of sepsis and hope for new therapeutics Curr. Infect. Dis. Rep. 14 2012 474 483
112. Glaxosmithkline, G.C.T. 2014. Effect of SRT2379 on Endotoxin-Induced Inflammation - Full Text View - ClinicalTrials.gov. [online] Available at: http://clinicaltrials.gov/ct2/show/NCT01262911 (Accessed: 27 Mar 2014).
113. M.A. Wiewel, A.J. Van Der Meer, J. Haddad, E.W. Jacobson, G.P. Vlasuk, and T. Van Der Poll SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Crit. Care 17 Suppl. 4 2013 8
114. S. Opal, and V.A. DePalo Anti-inflammatory cytokines Chest 117 2000 1162 1172
115. Y. Yang, N. Zhang, F. Lan, K. Van Crombruggen, L. Fang, G. Hu, S. Hong, and C. Bachert Transforming growth factor-beta 1 pathways in inflammatory airway diseases Allergy 69 2014 699 707
116. I. Raphael, S. Nalawade, T.N. Eagar, and T.G. Forsthuber T cell subsets and their signature cytokines in autoimmune and inflammatory diseases Cytokine 74 2015 5 17
117. M.A. Perrella, C.M. Hsieh, W.S. Lee, S. Shieh, J.C. Tsai, C. Patterson, C.J. Lowenstein, N.C. Long, E. Haber, S. Shore, and M.E. Lee Arrest of endotoxin-induced hypotension by transforming growth factor beta 1 Proc. Natl. Acad. Sci. U. S. A. 93 1996 2054 2059
118. J.M. Baumhofer, B.G. Beinhauer, J.A. Wang, H. Brandmeier, K. Geissler, U. Losert, R. Philip, G. Aversa, and M.A. Rogy Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence Eur. J. Immunol. 28 1998 610 615
119. M. Howard, T. Muchamuel, S. Andrade, and S. Menon Interleukin 10 protects mice from lethal endotoxemia J. Exp. Med. 177 1993 1205 1208
120. T. Van der Poll, A. Marchant, A. Buurman, L. Berman, C.V. Keogh, D.D. Lazarus, L. Nguyen, M. Goldman, L.L. Moldawer, and S.F. Lowry Endogenous IL-10 protects mice from death during septic peritonitis J. Immunol. 155 1995 5397 5401
121. G.Y. Song, C. Chung, H. Chaudry, and A. Ayala What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 126 1999 378 383
122. O. Hultgren, M. Kopf, and A. Tarowski Outcome of Staplylococcus aureus - triggered sepsis and arthritis in IL-4 deficient mice depends on the genetic background of the host Eur. J. Immunol. 29 1999 2400 2405
123. G.P. Otto, M. Sossdorf, R.A. Clauss, J. Rodel, K. Menge, K. Reinhart, M. Bauer, and N.C. Riedemann The late phase of sepsis is characterised by an increased microbiological burden and death rate Crit. Care 15 2011 R183
124. C.M. Coopersmith, P.E. Sromberg, W.M. Dunne, C.G. Davis, D.M. Amiot, T.G. Buchman, I.E. Karl, and R.S. Hotchkiss Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis JAMA 287 2002 1716 1721
125. R.S. Hotchkiss, G. Monneret, and D. Payen Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy Nat. Rev. Immunol. 13 2013 862 874
126. Y. Okazaki, and A. Matsukawa Pathophysiology of sepsis and recent patents on the diagnosis, treatment and prophylaxis for sepsis Recent Patents Inflamm. Allergy Drug Discov. 3 2009 26 32
127. Adib-Conquy M, Cavaillon JM. Compensatory anti-inflammatory response syndrome. Thromb. Haemost.; 101: 36-47.
128. S.P. Tzung, T.C. Mahl, P. Lance, V. Anderson, and S.A. Cohen Interferon-alpha prevents endotoxin-induced mortality in mice Eur. J. Immunol. 22 1992 3097 3101
129. G. Trinchieri Type 1 interferon: friend or foe? J. Exp. Med. 207 2010 2053 2063
130. I. Kötter, V. Hamuryudan, Z.E. Oztürk, and H. Yazici Interferon therapy in rheumatic diseases: state-of-the-art 2010 Curr. Opin. Rheumatol. 22 2010 278 283
131. K.L. Brzoza-Lewis, J.J. Hoth, and E.M. Hiltbold Type I interferon signaling regulates the composition of inflammatory infiltrates upon infection with listeria monocytogenes Cell. Immunol. 273 2012 41 51
132. N. Gratz, H. Hartweger, U. Matt, F. Kratochvill, M. Janos, S. Sigel, B. Drobits, X.D. Li, S. Knapp, and P. Kovarik Type I interferon production induced by Streptococcus pyogenes-derived nucleic acids is required for host protection PLoS Pathog. 7 5 2011 May e1001345 10.1371/journal.ppat.1001345 (Epub 2011 May 19)
133. J. Unsinger, M. McGlynn, K.R. Kasten, A.S. Hoekzema, E. Watanabe, J.T. Muenzer, J.S. McDonough, J. Tschoep, T.A. Ferguson, J.E. McDunn, M. Morre, D.A. Hildeman, C.C. Caldwell, and R.S. Hotchkiss IL-7 promotes T cell viability, trafunctionality and improves survival in sepsis J. Immunol. 184 2010 3768 3779
134. E.D. Carrol Comment on "IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis" J. Immunol. 185 2010 789
135. K.R. Kasten, P.S. Prakash, J. Unsinger, H.S. Goetzman, L.G. England, C.M. Cave, A.P. Seitz, C.N. Mazuski, T.T. Zhou, M. Morre, R.S. Hotchkiss, D.A. Hildeman, and C.C. Caldwell Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis Infect. Immun. 78 2010 4714 4722
136. R.S. Hotchkiss, G. Monneret, and D. Payen Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Lancet Infect. Dis. 13 2013 260 268
137. + T-regulatory cells J. Immunother. 29 2006 313 319
138. F. Venet, A. Foray, A. Villars-Mechin, C. Malcus, F. Poitevin-Later, A. Lepape, and G. Monneret IL-7 restores lymphocyte functions in septic patients J. Immunol. 189 2012 5073 5081
139. J.C. Andreu-Ballester, C. Cuellar, C. Garcia-Ballesteros, J. Pérez-Griera, V. Amigó, A. Peiró-Gómez, C. Peñarroja-Otero, F. Ballester, J. Mayan, and C. Tormo-Calandín Deficit of interleukin 7 in septic patients Int. Immunopharmacol. 23 2014 73 76
140. C. Meisel, J.C. Schefold, R. Pschowski, T. Baumann, K. Hetzger, J. Gregor, S. Weber-Carstens, D. Hasper, D. Keh, H. Zuchermann, P. Reinke, and H. Volk Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial Am. J. Respir. Crit. Care Med. 180 2009 640 648
141. M.W. Hall, N.L. Knatz, C. Vetterly, S. Tomarello, M.D. Wewers, H.D. Volk, and J.A. Carcillo Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome Intensive Care Med. 37 2011 525 532
142. D. Xu, M. Zhoe, Y. Song, J. Song, Y. Huang, and J. Wang Novel insights in preventing gram-negative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis and immune system Hepatol. Int. 9 2015 28 34
143. W.D. Docke, F. Randow, U. Syrbe, D. Krausch, K. Asadullah, P. Reinke, H.D. Volk, and W. Kox Monocyte deactivation in septic patients: restoration by IFN-gamma treatment Nat. Med. 3 1997 678 681
144. H.C. Polke Jr., C. W.G, D.H. Livingston, J.L. Rodriguez, K.M. Starko, A.E. Izu, H.S. Jaffe, and G.A. Sonnenfeld Randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients Am. J. Surg. 163 1992 191 196
145. L. Bo, F. Wang, J. Zhu, J. Li, and X. Deng Granulocyte -colony stimulating factor (G-CSF) and granulocyte - macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis Crit. Care 15 2011 R58
146. A.M. de Bruin, S.F. Libregts, M. Valkhof, L. Boon, I.P. Touw, and M.A. Nolte IFNγ induces monopoiesis and inhibits neutrophil development during inflammation Blood 119 2012 1543 1554
147. J. Leentjens, M. Kox, R. Koch, M. Preijers, F. Joosten, L.A. Van Der Hoeven, J.G. Netea, and M.G.P. Pickkers Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study Am. J. Respir. Crit. Care Med. 186 2012 838 845
148. K. Muthu, L.K. He, A. Szilagyi, J. Stevenson, R.L. Gamelli, and R. Shankar Propranolol restores tumour necrosis factor-α response of circulating inflammatory monocytes and granulocytes after burn injury and sepsis J. Burn Care Res. 30 2009 8 18
149. N.M. Novotny, T. Lahm, T.A. Markel, P.R. Crisostomo, M. Wang, Y. Wang, R. Ray, J. Tan, D. Al-Azzawi, and D.R. Meldrum Beta-blockers in sepsis: re-examining the evidence Shock 31 2009 113 119
150. A. Micheletti, F. Calzetti, O. Perbellinin, G. Pizzolo, M.A. Cassatella, and C. Constantini Neutrophil activation and survival are modulated by interaction with NK cells Int. Immunol. 22 2010 827 838
151. H.S. Panitch, R.L. Hirsch, A.S. Haley, and K.P. Johnson Exacerbations of multiple sclerosis in patients treated with gamma interferon Lancet 1 1987 893 895
152. J.C. Alves-Filho, F. Sônego, F.O. Souto, A. Freitas, W.A. Verri Jr., M. Auxiliadora-Martins, A. Basile-Filho, A.N. McKenzie, D. Xu, F.Q. Cunha, and F.Y. Liew Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection Nat. Med. 16 2010 708 712
153. J.-M. Cavaillon, D. Eisen, and D. Annane Is boosting the immune system in sepsis appropriate? Crit. Care 18 2014 216 http://ccforum.com/content/18/2/216